Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine-nab-paclitaxel failure: a propensity score-matched analysis
吉西他滨-白蛋白紫杉醇治疗失败后,转移性胰腺癌二线治疗方案为5-氟尿嘧啶联合纳米脂质体伊立替康对比FOLFOX/XELOX方案:倾向评分匹配分析
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105874
Trovato, G; Rossini, D; Guidolin, A; Su, Y-Y; Shan, Y-S; Chiang, N-J; Chou, W-C; Bai, L-Y; Bagalà, C; Bensi, M; Niger, M; Marchesi, S; Garattini, S K; Michelotti, A; Pretta, A; Scartozzi, M; Vivaldi, C; Bartalini, L; Procaccio, L; Bergamo, F; Antonuzzo, L; Chen, L-T; Salvatore, L; Tortora, G